In the present study, we compared the clinical outcomes of NSCLC patients treated with ICIs as second-line or further-line therapy after treatment failure with platinum-based cytotoxic chemotherapy according to the GPS values and explored the prognostic role of GPS values for treatment outcomes. We found that the baseline characteristics were not different according to GPS. Patients with higher GPS values displayed shorter median irPFS and OS than those in the GPS 0 or GPS 1 groups. In multivariate analysis, higher PD-L1 expression was negatively associated and higher GPS was positively associated with shorter irPFS and OS.
Chronic inflammation is known to be associated with tumor development through the induction of oncogenic mutations, genomic instability, early tumor promotion, and enhanced angiogenesis [9]. Various cancers induce an inflammatory microenvironment [10]. Nutrition is a critical component of immune responses [11]. In lung cancer, systemic inflammation, malnutrition, and tumor immune microenvironments are associated with each other, and these are key determinants of tumor progression and treatment response [3]. Elevated levels of circulating CRP could be a marker of the increased predisposition to malignancy due to chronic inflammation, a marker of occult cancer leading to inflammation, or both [10].
In the era of immunotherapy in cancer treatment, proper predictive factors of NSCLC patients for immunotherapy have not been developed. The expression of PD-L1 on tumor cells and the TMB have been used in qualifying patients to receive immunotherapy, but not all patients with these predictive factors benefit from immunotherapy [2]. Patients with high TMB who received nivolumab and ipilimumab did not show significant survival benefit compared to those who received chemotherapy [12]. The presence of immune cells in the anti-tumor immune response such as cluster of differentiation (CD)8-positive cytotoxic T lymphocytes as well as CD4-positive memory and regulatory T lymphocytes has been postulated as a prognostic marker of the disease course and predictors of activity or modulation of immune system function [13]. For simpler analysis, systemic inflammatory marker such as lung immune prognostic index which could be performed in clinical practice are suggested as biomarker for ICIs in lung cancer. Poor lung immune prognostic index combining the derived NLR and the LDH value is associated with poorer outcomes in patients treated with ICIs [14].
Several studies demonstrated that systemic inflammatory biomarkers in peripheral blood were predictive markers for treatment outcomes in different solid tumors including prostate, colorectal, and esophageal cancer, melanoma, and NSCLC [15–19]. Although the exact biological basis for these findings has not been thoroughly elucidated, inflammatory cells such as neutrophils play a significant role in tumor development and progression via effects on tumor cells or other components of the tumor microenvironment by secreting chemokines and cytokines such as transforming growth factor-ß, interleukin-6 (IL-6), and matrix metalloproteinase [20, 21]. CRP is a surrogate marker of IL-6, which is involved in the activation of immune cells, tumor migration and invasion, and epithelial-to-mesenchymal transition [22, 23].
Cancer prognosis is associated with not only tumor staging but also patient-related factors such as nutritional and functional decline. CRP represents systemic inflammation, and albumin reflects both systemic inflammation and the amount of lean tissue [24, 25]. GPS is a reliable independent prognostic factor in patients with various malignancies and also a marker for predicting prognosis, even in surgery, chemoradiation, and various subgroups incapable of surgery [5, 6]. In 15 studies including > 2,000 patients, GPS was associated with increased weight loss, poor performance status, increased comorbidity, increased proinflammatory and angiogenic cytokines, and complications from cancer treatments [5].
Few previous studies on the association between GPS and clinical outcomes in lung cancer patients treated with ICIs have been conducted. Taichi et al. reported that pretreatment modified GPS values were associated with shorter OS in NSCLC patients treated with atezolizumab [26]. In another study, post-treatment GPS predicted anti-PD1 treatment (nivolumab or pembrolizumab) efficacy in NSCLC patients [27]. These studies had small sample sizes from single institutions and reported the results of groups treated with anti-programmed cell death protein 1 (PD1) or anti-PD-L1 antibody. Our study had a large sample size and analyzed the prognostic role of pre-treatment GPS values in all of the NSCLC patients treated with anti-PD1 or anti-PD-L1 antibodies.